Michael Logan (M Logan)

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 5

Top Topics

Irritable Bowel Syndrome

Disease Activity

Top Venues

Alimentary pharmacology & therapeutics

BMC gastroenterology

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Logan, Mary MacKinder, Clare Martha Clark, Aikaterini Kountouri, Mwansa Jere, Umer Zeeshan Ijaz, Richard Hansen, Paraic McGrogan, Richard Kay Russell, Konstantinos Gerasimidis
Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn's disease. BMC gastroenterology 22 (1) (2022)
Michael Logan, Konstantinos Gkikas, Vaios Svolos, Ben Nichols, Simon W F Milling, Daniel R Gaya, John Paul Seenan, Jonathan Macdonald, Richard Hansen, Umer Zeeshan Ijaz, Richard Kay Russell, Konstantinos Gerasimidis
Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn's disease-new insights into dietary disease triggers. Alimentary pharmacology & therapeutics 51 (10) (2020)
Michael Logan, Clare M Clark, Umer Zeeshan Ijaz, Lisa Gervais, Hazel Duncan, Vikki Garrick, Lee Curtis, Elaine Buchanan, Tracey Cardigan, Lawrence Armstrong, Caroline Delahunty, Diana M Flynn, Andrew R Barclay, Rachel Tayler, Elizabeth McDonald, Simon Milling, Richard K Hansen, Konstantinos Gerasimidis, Richard Kay Russell
The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction. Alimentary pharmacology & therapeutics 50 (6) (2019)
Orges Koci, Michael Logan, Vaios Svolos, Richard Kay Russell, Konstantinos Gerasimidis, Umer Zeeshan Ijaz
An automated identification and analysis of ontological terms in gastrointestinal diseases and nutrition-related literature provides useful insights. PeerJ 6 (2018)
Michael Logan, Umer Zeeshan Ijaz, R Hansen, Konstantinos Gerasimidis, R K Russell
Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease. Alimentary pharmacology & therapeutics 46 (11-12) (2017)